Biogen to Acquire Nightstar Therapeutics for $800M

 Biogen to Acquire Nightstar Therapeutics for $800M

Biogen to Acquire Nightstar Therapeutics for $800M

Shots:

  • Biogen acquires Nightstar Therapeutics, in all stock transaction with its lead candidates NSR-REP1 & NSR-RPGR. Nightstar Therapeutics to receive $25.50 /share in cash for one day premium of 68% on closing of $15.16 making the total deal value $800M
  • The focus of an acquisition is to strengthen Biogen’s portfolio in ophthalmology. Biogen expected to complete the acquisition in H2’19
  • NST’s NSR-REP1 & NSR-RPGR are subretinal injections based on AVV vector used for the treatment of choroideremia (CHM) & X-linked retinitis pigmentosa (XLRP) respectively

Click here to read full press release/ article | Ref: Biogen | Image: Wall Street Journal

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post